LAUSR

Identifying patients with idiopathic pulmonary fibrosis (IPF) at the earliest opportunity remains one of the most urgent challenges for the effective management of this deadly disease. A theoretical basis for early IPF detection comes from large lung cancer and cardiovascular cohort studies that have reported shared clinical associations between incidentally detected subclinical interstitial lung abnormalities (ILAs) on computed tomography (CT) and IPF (1). ILAs are more prevalent with increasing age (2–4), in smokers (1, 5, 6), and in patients over the age of 50 who exhibit MUC5B promoter polymorphism positivity (4). ILAs are also associated with a reduction in pulmonary function (1, 5) and exercise capacity (7). Importantly, patients with progressive ILAs demonstrate greater serial pulmonary function decline when compared with patients with stable ILAs (8). However, the consistent observation that ILA prevalence exceeds that of IPF by more than an order of magnitude means that refinement of current ILA definitions and identification of progressive ILA subtypes are critical if screening for early IPF is to be successful (1). In this issue of the Journal, Putman and colleagues (pp. 175– 183) extend their impressive portfolio of ILA studies by evaluating the impact of specific ILA features on ILA progression as judged by follow-up CT in a population of adults from the AGESReykjavik (Age, Gene/Environment Susceptibility–Reykjavik) study (9). This study is important because it represents the first attempt to identify specific CT features and radiologic patterns linked to the progressive ILA phenotype. ILAs defined as subpleural and reticular, those associated with traction bronchiectasis, and ILAs with a lower-lobe predilection were associated with a greater than sixfold likelihood of progression. Moreover, in 16 patients with ILAs characterized by honeycombing, all five who had follow-up imaging had progressed. The authors also generated a “definite fibrosis” score by amalgamating traction bronchiectasis and honeycombing, which was associated with a greater than eightfold likelihood of progression. Finally, previously reported clinical associations with ILA progression, including increasing age and MUC5B promoter polymorphism positivity, were confirmed. The importance of standardizing ILA definitions cannot be overstated, and the authors make a considerable effort to maintain consistency and clarity in this regard. However, two issues warrant consideration. First, the separation of fibrotic from nonfibrotic ILA is crucial but challenging in limited or early disease because CThistologic correlation in this setting is imperfect. In one patient, limited subpleural reticulation may be the sole CT manifestation of advanced fibrosis histologically, but in another patient it may not represent fibrosis at all (10). The authors attempt to address this issue by combining traction bronchiectasis and honeycombing, two reliable CT signs of fibrosis, as one variable (“definite fibrosis”), but this is likely to miss at least some cases of reticular ILA representing real fibrotic disease. It is interesting to note that the latest iteration of the international evidence-based joint clinical practice guideline for IPF diagnosis includes in its definition of “indeterminate” for usual interstitial pneumonia (UIP) on CT “subtle reticulation,” which is also described as an “early UIP” pattern (11). In the study by Putman and colleagues, the prevalence of reticular ILA is more than 80%, but only 34% of these cases were considered to represent “definite fibrosis” (9). The second, related issue is that if “definite fibrosis” is confined to ILAs in which traction bronchiectasis or honeycombing is present, what defines the boundary between this subtype of fibrotic ILA and the presence of established fibrotic lung disease? In the study by Putman and colleagues, patients whose pattern of ILA met guideline criteria for “probable” or “definite” UIP were included in the analysis and, as expected, all of these patients progressed. Furthermore, 89%/100% of those with a “probable”/“definite” UIP pattern, respectively, died at the end of the follow-up period. The inclusion of these patients raises questions regarding the overarching definition of ILA: “imaging abnormalities on chest CT in research participants without a clinical diagnosis of interstitial lung disease.” Based on current guidelines, the majority of these patients would meet diagnostic criteria for IPF (11). Although there is currently no evidence showing that a UIP pattern on chest CT predicts outcome in research participants who have not received a diagnosis, our understanding of UIP as the prototypic progressive radiologic phenotype is supported by a large body of evidence across idiopathic and nonidiopathic fibrotic lung disease cohorts (12–15). If a screening strategy for detecting early IPF is to be successful, we should probably focus our efforts on determining which of the ILAs that are currently considered nonspecific represent early and clinically relevant progressive fibrotic lung disease (Figure 1). Undoubtedly, a set of standard definitions that would allow consistent ILA reporting and harmonization of cohorts to power larger studies is urgently required. How these definitions should be devised is less clear. Taxonomy can be a double-edged sword that, when wielded indiscriminately, merely replaces understanding with filing—the crux of the well-known “lumping and splitting” debate. Categories that are too rigorously defined lead to distinctions without a difference or impracticable precision, particularly when knowledge is incomplete. Overlapping ILA patterns may exist that by definition cannot be easily placed within a single category. ILA distribution in three dimensions is also likely to be significant based on our